Get the Stockscreener App
23.36
2.34%
-0.56
After Hours:
23.00
-0.36
-1.54%
Elanco Animal Health Inc stock is traded at $23.36, with a volume of 3.15M.
It is down -2.34% in the last 24 hours and down -7.30% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$23.92
Open:
$23.23
24h Volume:
3.15M
Relative Volume:
0.63
Market Cap:
$11.61B
Revenue:
$4.72B
Net Income/Loss:
$-232.00M
P/E Ratio:
-50.10
EPS:
-0.4663
Net Cash Flow:
$284.00M
1W Performance:
-11.52%
1M Performance:
-7.30%
6M Performance:
+26.75%
1Y Performance:
+115.70%
1-Day Range:
$22.93
$23.61
1-Week Range:
$22.93
$26.35
52-Week Range:
$8.02
$27.72
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
450 ELANCO CIRCLE, INDIANAPOLIS
Compare ELAN vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
23.36 | 11.89B | 4.72B | -232.00M | 284.00M | -0.4663 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.88 | 56.11B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
121.43 | 51.60B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.28 | 46.00B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.05 | 36.98B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
478.16 | 21.26B | 3.13B | 1.27B | 1.12B | 26.39 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-21-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-19-25 | Upgrade | Argus | Hold → Buy |
| Oct-07-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-17-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jun-26-25 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
How Elanco Animal Health Incorporated stock performs in high volatility marketsJuly 2025 Price Swings & Real-Time Market Sentiment Alerts - Naître et grandir
Teachers Retirement System of The State of Kentucky Purchases Shares of 110,000 Elanco Animal Health Incorporated $ELAN - MarketBeat
Injected Veterinary Pain Management Drugs Market Set to Witness - openPR.com
Picton Mahoney Asset Management Invests $7.49 Million in Elanco Animal Health Incorporated $ELAN - MarketBeat
Dimensional Fund Advisors LP Has $497.61 Million Stock Position in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Incorporated $ELAN Shares Sold by Black Creek Investment Management Inc. - MarketBeat
Elanco (ELAN) EVP awarded stock, options and disposes shares for taxes - Stock Titan
Elanco (NYSE: ELAN) CEO receives large stock grants and tax share sale - Stock Titan
Elanco (ELAN) CAO reports RSU grants and tax-withholding share disposal - Stock Titan
Elanco (ELAN) executive logs new stock grants and tax withholding share disposal - Stock Titan
Elanco (ELAN) CFO VanHimbergen receives new stock and option grants - Stock Titan
Elanco (ELAN) executive equity awards and tax share withholding detailed - Stock Titan
ELAN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Royce & Associates LP Buys 105,632 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Agriculture Biotechnology Industry Research and Global Forecast Report 2025-2030, Profiles of Prominent PlayersBayer, Corteva Agriscience, BASF, Syngenta, Zoetis, Elanco Animal Health, Novonesis - GlobeNewswire
Elanco at TD Cowen Conference: Strategic Growth and Industry Outlook - Investing.com
Elanco Animal Health (ELAN) Stock Analysis: Navigating a 8.97% Potential Upside in the Booming Animal Health Market - DirectorsTalk Interviews
Elanco Animal Health Incorporated (NYSE:ELAN) Short Interest Update - MarketBeat
TD Asset Management Inc Has $21.87 Million Stock Holdings in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health (ELAN) Is Up 5.7% After Beating Q4 Views And Raising 2026 Innovation Outlook - simplywall.st
JPMorgan Chase & Co. Buys 1,394,839 Shares of Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco Animal Health Q4 2025 Earnings Highlights - Intellectia AI
PetMed, Elanco, Tractor Supply Settle Flea & Tick Med Claims - Law360
Elanco (ELAN) Q4 2025 Earnings Call Transcript - AOL.com
Chewy reaches settlement in Elanco flea and tick antitrust litigation - DVM360
Elanco Animal Health Q4 Loss Deepens And Tests Bullish Profitability Narratives - simplywall.st
Amlan International and Elanco Collaborate on Japanese Educational Seminars Focused on Calf Health - Yahoo Finance
Jim Cramer Highlights Elanco’s “Comeback Story” - Yahoo Finance
Primecap Management Co. CA Has $1.01 Billion Stake in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco’s AHV Deal And Befrena Win Reshape Growth And Valuation Story - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and Henry Schein (HSIC) - The Globe and Mail
Morgan Stanley Raises Price Target for Elanco Animal Health (ELA - GuruFocus
Elanco Animal Health (NYSE:ELAN) Given New $24.00 Price Target at Morgan Stanley - MarketBeat
Keybanc Raises Price Target for ELAN, Maintains Overweight Ratin - GuruFocus
Elanco Animal Health (NYSE:ELAN) Given New $29.00 Price Target at KeyCorp - MarketBeat
KeyBanc raises Elanco Animal Health price target on product strength By Investing.com - Investing.com Canada
Elanco Animal Health Incorporated (NYSE:ELAN) Q4 2025 Earnings Call Transcript - Insider Monkey
Ameritas Investment Partners Inc. Invests $1.88 Million in Elanco Animal Health Incorporated $ELAN - MarketBeat
Elanco (ELAN) Surpasses Revenue Expectations and Forecasts Growt - GuruFocus
Decoding Elanco Animal Health Inc (ELAN): A Strategic SWOT Insig - GuruFocus
Elanco (ELAN) Focuses on Growth through Innovation and Cash Flow Management - GuruFocus
Elanco (ELAN) officer granted 56.63 deferred stock units in Form 4 - Stock Titan
Elanco (ELAN) CEO Jeffrey Simmons awarded new deferred stock units - Stock Titan
Elanco (NYSE: ELAN) CFO receives new deferred stock unit grant - Stock Titan
Elanco Animal Health Q4 Earnings Call Highlights - MarketBeat
Elanco Animal Health Inc (ELAN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ... By GuruFocus - Investing.com Canada
Elanco Animal Health (ELAN) Receives Outperform Rating with Rais - GuruFocus
Elanco Animal Health (NYSE:ELAN) Price Target Raised to $30.00 at Leerink Partners - MarketBeat
Elanco Animal Health Shares Rise After Q4 Beat - marketscreener.com
Elanco Working To Enhance Tools To Address New World Screwworm - Southeast AgNET
Elanco Animal Health Incorporated Q4 2025 Earnings Call Summary - Yahoo Finance
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.55%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):